Alastair Logan

Developing standards for the microbiome field

Gregory C. A. Amos, Alastair Logan, Saba Anwar et al. · Microbiome · 2020 · 126 citations · Full text

An Improved Small-Molecule Inhibitor of FtsZ with Superior <i>In Vitro</i> Potency, Drug-Like Properties, and <i>In Vivo</i> Efficacy

Neil R. Stokes, Nicola Baker, James M. Bennett et al. · Antimicrobial Agents and Chemotherapy · 2012 · 97 citations · Full text

Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors

Lorraine C. Axford, Piyush K. Agarwal, Kelly H. Anderson et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 35 citations · Full text

Medicinal Chemistry, Antimicrobial Drug Discovery, Biochemistry +8

Biological Evaluation of Benzothiazole Ethyl Urea Inhibitors of Bacterial Type II Topoisomerases

Neil R. Stokes, Helena Thomaides‐Brears, Stephanie Barker et al. · Antimicrobial Agents and Chemotherapy · 2013 · 34 citations · Full text

Bioorganic Chemistry, Antiparasitic Agent, Antimicrobial Chemotherapy +22

Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations

Gregory C. A. Amos, Chrysi Sergaki, Alastair Logan et al. · Scientific Reports · 2021 · 31 citations · Full text

Inflammation, Chronic Inflammatory Diseases, Microbiome Signatures +14